Skip to main content

Insulin glulisine Side Effects

Medically reviewed by Last updated on Aug 2, 2023.

Applies to insulin glulisine: parenteral injection.

Side effects include:

Hypoglycemia, systemic hypersensitivity, injection site reaction.

For Healthcare Professionals

Applies to insulin glulisine: injectable solution, subcutaneous solution.


The most common adverse reactions reported include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash.[Ref]


Common (1% to 10%): Hypoglycemia, hypoglycemic seizure

Frequency not reported: Weight gain[Ref]


Common (1% to 10%): Local hypersensitivity reactions (redness, swelling, and itching at injection site) Uncommon (0.1% to 1%): Systemic allergic reactions including urticaria, chest tightness, dyspnea, allergic dermatitis, and pruritus

Frequency not reported: Anaphylaxis[Ref]

In clinical trials of ups to 12 months duration, potential systemic allergic reactions were reported in 4.3% (79 of 1833) patients receiving insulin glulisine compared with 3.8% (58 of 1524) patients receiving comparator short-acting insulins. Permanent discontinuation occurred in 1 patient receiving insulin glulisine.[Ref]


Among patients using continuous subcutaneous insulin infusion pumps, the rates of catheter occlusions and infusion site reactions were similar with insulin glulisine compared with insulin aspart.[Ref]

Common (1% to 10%): Infusion site reactions

Very rare (less than 0.01%): Catheter occlusions[Ref]


Common (1% to 10%): Peripheral edema, hypertension[Ref]


Common (1% to 10%): Diarrhea, pharyngitis, vomiting, nausea[Ref]


Rare (less than 0.1%): Lipodystrophy[Ref]


Common (1% to 10%): Influenza[Ref]


Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection, sinusitis, bronchitis[Ref]


Common (1% to 10%): Arthralgia, back pain[Ref]

Nervous system

Common (1% to 10%): Headache[Ref]


Common (1% to 10%): Urinary tract infection[Ref]

Frequently asked questions


1. Product Information. Apidra (insulin glulisine). Aventis Pharmaceuticals. 2004.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.